obesity

News

AI specialist Fauna grabs $494m Lilly obesity alliance

A US biotech that is trying to find new avenues for treating human diseases by studying the genomics of animal species, Fauna Bio, has agreed a deal with Eli Lilly focusin

Market Access

Nine for 2024, Pt 1: From fragility to resilience

This year was a year of significant new beginnings for pharma and healthcare, yet, it was still impacted by the long-term fallouts of the pandemic.

News

Pfizer drops twice-daily obesity therapy due to side effects

Pfizer has decided to discontinue the development of another of its experimental obesity therapies, after seeing high rates of discontinuation with the drug in a mid-stage

News

Roche makes obesity play with $2.7bn deal to buy Carmot

Roche has agreed a deal to acquire US biotech Carmot Therapeutics that, if consummated, will thrust it into the increasingly competitive market for incretin-based therapie

News

AHA: Wegovy improves survival in outcomes trial

Novo Nordisk’s obesity therapy Wegovy has cut the risk of death by 19% in the SELECT trial, mirroring the benefits of the drug in cardiovascular outcomes in people who are

R&D

While diabetes & obesity fund Novo Nordisk, its Foundation f...

The Novo Nordisk Foundation is not a charitable organisation owned by the pharma company Novo Nordisk. In fact, it’s the other way around, more or less.

AI specialist Fauna grabs $494m Lilly obesity alliance

Nine for 2024, Pt 1: From fragility to resilience

Pfizer drops twice-daily obesity therapy due to side effects

Roche makes obesity play with $2.7bn deal to buy Carmot

AHA: Wegovy improves survival in outcomes trial

While diabetes & obesity fund Novo Nordisk, its Foundation f...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

obesity

Editor's Picks